drugset
drugset / Trial / NCT05951049

A Study of AT-02 in Subjects With Systemic Amyloidosis.

NCT05951049 ↗

Phase 2 Active not recruiting 120 enrolled Attralus, Inc. Novotech (Australia) Pty Limited · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.

Timeline

Start
2023-09-21
Primary completion
2026-09-28
Completion
2026-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject AT02 Monoclonal antibody — Intravenous

Indications

amyloidosis